Thioguanine as primary treatment for chronic granulocytic leukaemia
| Autor: | Juginder Kaur, J.M. Goldman, A.S.D. Spiers, D.A.G. Galton |
|---|---|
| Rok vydání: | 1975 |
| Předmět: |
Adult
Male medicine.medical_specialty Neutropenia Neutrophils Allopurinol Population Gastroenterology Primary therapy Hemoglobins Leukocyte Count hemic and lymphatic diseases Internal medicine medicine Chromosomes Human 21-22 and Y Humans Initial therapy education Thioguanine education.field_of_study business.industry Chronic granulocytic leukaemia Negativity effect General Medicine Middle Aged medicine.disease Alkaline Phosphatase Hematopoietic Stem Cells Leukemia Myeloid Immunology Drug Evaluation Primary treatment Drug Therapy Combination Female business |
| Zdroj: | Lancet (London, England). 1(7911) |
| ISSN: | 0140-6736 |
| Popis: | In an attempt to convert the bone-marrow population from Philadelphia- chromosome (Ph 1 ) positive to partially or wholly Ph 1 negative, thioguanine was used as primary therapy in seven patients with chronic granulocytic leukaemia (C.G.L.). Although eight episodes of neutropenia were induced, prolonged remission or conversion to Ph 1 - negativity was not achieved in any patient. However, thioguanine was at least as effective as busulphan for initial therapy in C.G.L., and had the advantage of rapid reversibility of haemopoietic depression when discontinued. Thioguanine merits further evaluation as an agent for the management of C.G.L. in its chronic phase. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|